NCT04899518

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

A Phase 2b/3, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease (OASIS-1)

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 922 (actual)
• Sponsor: Allysta Pharmaceutical · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease

Detailed description

Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease

Conditions

• Dry Eye

Interventions

Type	Name	Description
DRUG	ALY688 Ophthalmic Solution	Ophthalmic Solution

Timeline

• Start date: 2021-05-19
• Primary completion: 2023-03-14
• Completion: 2023-03-14
• First posted: 2021-05-24
• Last updated: 2023-03-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study